HDT Bio Canada Inc. partners with McGill University and The Neuro to advance HDT-401, an investigational locally administered RNA immune activator, into Phase 1 clinical evaluation for glioblastoma in CanadaMONTREAL and SEATTLE, July 12, 2026 /PRNewswire/ — Among…

Read the full release →

News provided by PR Newswire.